The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Subscribe To Our Newsletter & Stay Updated
